AGM/EGMSep 29, 2026, 04:11 PM
Cadrenal Therapeutics Stockholders Approve Equity Plan Increase and Director Election
AI Summary
Cadrenal Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on September 24, 2026. Key outcomes included the approval of an amendment to the 2022 Successor Equity Incentive Plan, increasing the number of shares available for awards by 323,542 to 1,000,000. Stockholders also ratified the appointment of WithumSmith+Brown, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and elected Quang X. Pham as a Class I director. Additionally, the issuance of up to 960,000 shares of Common Stock upon the exercise of Series C-1 warrants was approved.
Key Highlights
- Cadrenal Therapeutics' stockholders approved an amendment to the 2022 Successor Equity Incentive Plan, increasing available shares by 323,542 to 1,000,000.
- The company's stockholders ratified the appointment of WithumSmith+Brown, P.C. as the independent registered public accounting firm for fiscal year 2026.
- Quang X. Pham was elected as a Class I director, to serve until the Company’s 2029 annual meeting of stockholders.
- Stockholders approved the issuance of up to 960,000 shares of Common Stock upon the exercise of Series C-1 warrants.
- The 2026 Annual Meeting of Stockholders was held on September 24, 2026, with 2,155,341 shares of Common Stock represented.
Price Impact
More from CVKD